Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Lomitapide

Catalog No: tcsc3423

Available Sizes

Size: 10mg

Size: 50mg

Specifications

CAS No:
182431-12-5

Formula:
$C_{39}H_{37}F_6N_3O_2$

Pathway:
Others

Target:
Others

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 35 mg/mL (50.45 mM)

Alternative Names:
AEGR-733;BMS-201038

Observed Molecular Weight:
693.72

Product Description

Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (**MTP**) with an **IC_{50}** of 8 nM *in vitro*

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

.

IC50 & Target: IC50: 8 nM (MTP)[1]

In Vitro: Lomitapide is an oral microsomal triglyceride transfer protein (MTP) inhibitor indicated for the treatment of patients with HoFH, a rare form of hypercholesterolemia that can lead to premature atherosclerotic disease. Lomitapide undergoes hepatic metabolism via cytochrome P-450 (CYP) isoenzyme 3A4 and interacts with CYP3A4 substrates including atorvastatin and simvastatin [2].

In Vivo: The use of lomitapide alone or in combination with other lipid-lowering modalities reduces plasma concentrations of low density lipoprotein cholesterol (LDL-C) by a mean of more than 50%. Lomitapide is associated with significant gastrointestinal adverse effects and increases in hepatic fat levels. The bioavailability of the 50-mg lomitapide capsule is 7.1%. The mean half-life of lomitapide is 39.7 hours[2]. Single-dose administration of lomitapide is shown to reduce serum triglycerides by 35% and 47% at 0.3- and 1-mg/kg doses, respectively. Multiple-dose treatment with lomitapide also results in dose dependent decrease in triglycerides (71%–87%), nonesterified fattyacids(33%–40%), and LDL-C(26-29%)[3].